Penumbra (PEN) to Release Quarterly Earnings on Tuesday

Penumbra (NYSE:PEN) is expected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Penumbra to post earnings of $1.15 per share and revenue of $389.6440 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The company had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.83 EPS. On average, analysts expect Penumbra to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Penumbra Price Performance

Shares of PEN opened at $320.46 on Tuesday. The company’s fifty day moving average price is $319.32 and its 200-day moving average price is $330.05. The firm has a market capitalization of $12.60 billion, a PE ratio of 73.85, a price-to-earnings-growth ratio of 1.98 and a beta of 0.70. Penumbra has a 1-year low of $221.26 and a 1-year high of $362.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95.

Institutional Trading of Penumbra

Hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. increased its stake in shares of Penumbra by 16.4% during the fourth quarter. Pacer Advisors Inc. now owns 5,984 shares of the company’s stock worth $1,860,000 after buying an additional 844 shares during the period. Invesco Ltd. raised its holdings in shares of Penumbra by 1.1% in the 4th quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock valued at $198,455,000 after purchasing an additional 7,211 shares in the last quarter. Onyx Bridge Wealth Group LLC raised its holdings in shares of Penumbra by 411.9% in the 4th quarter. Onyx Bridge Wealth Group LLC now owns 26,780 shares of the company’s stock valued at $8,326,000 after purchasing an additional 21,549 shares in the last quarter. Vident Advisory LLC lifted its position in shares of Penumbra by 15.4% during the 4th quarter. Vident Advisory LLC now owns 1,607 shares of the company’s stock worth $500,000 after purchasing an additional 215 shares during the last quarter. Finally, State of Tennessee Department of Treasury boosted its position in shares of Penumbra by 61.7% during the 4th quarter. State of Tennessee Department of Treasury now owns 17,673 shares of the company’s stock worth $5,495,000 after acquiring an additional 6,744 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen raised shares of Penumbra to a “hold” rating in a report on Saturday, May 9th. Zacks Research cut Penumbra from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a report on Friday, July 17th. Citigroup cut their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Penumbra in a research report on Monday, July 6th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Penumbra presently has an average rating of “Hold” and a consensus target price of $360.33.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.